Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.38
-0.26 (-3.40%)
At close: Jul 14, 2025, 4:00 PM
7.39
0.00 (0.07%)
After-hours: Jul 14, 2025, 4:05 PM EDT
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $17.36M in the twelve months ending March 31, 2025, down -35.92% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$17.36M
Revenue Growth
-35.92%
P/S Ratio
17.07
Revenue / Employee
$108,522
Employees
160
Market Cap
337.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CAPR News
- 8 hours ago - Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha
- 2 days ago - Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Business Wire
- 3 days ago - Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock - Benzinga
- 3 days ago - Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 3 days ago - US FDA declines to approve Capricor's muscle disorder therapy - Reuters
- 3 days ago - Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy - GlobeNewsWire
- 20 days ago - FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy - Benzinga
- 20 days ago - US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters